Partnership for Collaborative Action
| Key collaborative partners |
| Research enterprise (public and private, researchers and funders) |
| Health care providers, including those providing home care |
| Community-based support |
| Patients and their family and friend caregivers |
| Policy makers and payers |
| An array of other essential partners (eg, government public health, foundations) |
| Domains of engagement for key partners |
| Formulating research questions and methods that address context |
| Reporting and interpreting research findings with greater attention to context |
| Disseminating findings and strengthening the evidence base in prevention, management, and care for persons with MCC |
| Translating findings into plain language in the patient’s context |
| Sustaining funding, advocacy, and other support for context in research and practice |
| Ongoing measurement and monitoring of progress and impact |
| Steps for building and sustaining collaborative partnership |
| Enumerate specific strategic partners |
| Establish common and compelling lexicons and stories |
| Engage partners |
| Foster innovation on context-informed research (eg, encourage funding announcements, FDA, IRBs to emphasize context-informed research) |
| Foster incorporation of context in practice (eg, cross-cutting clinical guidelines, performance measures, and patient-caregiver self-care management practice) |
| Continue reinforcing actions by partners |
| Measure and monitor effects and modulate actions |
FDA = Federal Drug Administration; IRB = institutional review board; MCC = multiple chronic conditions.